Structure Therapeutics Inc. $(GPCR)$, a clinical-stage global biopharmaceutical company, announced two upcoming late-breaking poster presentations at the American Diabetes Association 85th Scientific Sessions, taking place from June 20-23, 2025, in Chicago, IL. The presentations will include new preclinical data on ACCG-2671, an oral small molecule amylin agonist, which is expected to enter clinical development by the end of 2025. The preclinical studies highlighted significant weight-loss effects of ACCG-2671 alone and in combination with a GLP-1 receptor agonist in diet-induced obese rats. Additionally, data on a GLP-1 receptor agonist, GSBR-5595, will be presented, demonstrating neuroprotective effects in a Parkinson's disease mouse model. These findings will be shared on June 22, 2025, during the Late Breaking Poster Session at the event.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.